Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE BioTrends Research Group
Compared with 2012, in Certain Ulcerative Colitis Disease Severities, Remicade Usage Has Decreased Significantly, According to a New Report from BioTrends Research Group
EXTON, Pa., Oct. 23, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that although the patient share for Janssen's Simponi is low, gastroenterologists report a significant increase in use amongst their moderate and severe ulcerative colitis (UC) patients. Since 2012, there has also been a significant increase in use of AbbVie's Humira for maintenance of patients in remission, and use of Janssen's Remicade has significantly dropped for severe UC patients.
(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO )
The TreatmentTrends® Ulcerative Colitis (US) 2013 report finds that gastroenterologists continue to agree that there is an unmet need for new biologic and nonbiologic agents for the treatment of UC. Compared to 2012, their level of agreement on this unmet need is not as strong, and this is likely due to the fact that Humira and Simponi are newly approved since last year and are prescribed by significantly more gastroenterologists in 2013. When surveyed gastroenterologists were asked to rate attributes associated with available therapies for UC, Humira performs slightly better than Remicade on the top three attributes chosen by gastroenterologists.
"The approval of Humira and Simponi for the treatment of UC seems to have somewhat satisfied the unmet need of new therapies for UC," said BioTrends Senior Data Analyst Jen Dolga. "However, it is important to note that regardless of the fact that Remicade's use has decreased significantly over the past year for severe UC patients, it currently continues to hold more biologic patient share than any other biologic agent."
About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks of their respective holders.
For more information, contact:
©2012 PR Newswire. All Rights Reserved.